JP2016525516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525516A5 JP2016525516A5 JP2016526515A JP2016526515A JP2016525516A5 JP 2016525516 A5 JP2016525516 A5 JP 2016525516A5 JP 2016526515 A JP2016526515 A JP 2016526515A JP 2016526515 A JP2016526515 A JP 2016526515A JP 2016525516 A5 JP2016525516 A5 JP 2016525516A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mutation
- cytokine
- mutated
- leptin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000695 Cytokines Proteins 0.000 claims 10
- 102000004127 Cytokines Human genes 0.000 claims 10
- 230000035772 mutation Effects 0.000 claims 8
- 102000016267 Leptin Human genes 0.000 claims 4
- 108010092277 Leptin Proteins 0.000 claims 4
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 4
- 229940039781 leptin Drugs 0.000 claims 4
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims 3
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims 3
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 claims 2
- 102100035304 Lymphotactin Human genes 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 102200154281 rs267606652 Human genes 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306034 | 2013-07-18 | ||
| EP13306034.3 | 2013-07-18 | ||
| PCT/EP2014/064227 WO2015007536A2 (en) | 2013-07-18 | 2014-07-03 | Fusokines involving cytokines with strongly reduced receptor binding affinities |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019154901A Division JP6853317B2 (ja) | 2013-07-18 | 2019-08-27 | 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016525516A JP2016525516A (ja) | 2016-08-25 |
| JP2016525516A5 true JP2016525516A5 (cg-RX-API-DMAC7.html) | 2017-08-10 |
| JP6580037B2 JP6580037B2 (ja) | 2019-09-25 |
Family
ID=48906191
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526515A Active JP6580037B2 (ja) | 2013-07-18 | 2014-07-03 | 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン |
| JP2019154901A Active JP6853317B2 (ja) | 2013-07-18 | 2019-08-27 | 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019154901A Active JP6853317B2 (ja) | 2013-07-18 | 2019-08-27 | 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10640542B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3299466B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6580037B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102322510B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN110835376B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2014292371B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016001036B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2917937C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3299466T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2757501T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL243451B (cg-RX-API-DMAC7.html) |
| MX (1) | MX375441B (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201600163VA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015007536A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11702477B2 (en) | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| WO2017134301A1 (en) | 2016-02-05 | 2017-08-10 | Orionis Biosciences Nv | Clec9a binding agents |
| CN109069573B (zh) | 2016-03-07 | 2022-04-05 | 弗拉芒区生物技术研究所 | 结合cd20的单结构域抗体 |
| EP3455245A2 (en) | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| CN109689087B (zh) | 2016-05-13 | 2023-04-04 | 奥里尼斯生物科学私人有限公司 | 靶向性突变干扰素-β及其用途 |
| ES2917000T3 (es) | 2016-10-24 | 2022-07-06 | Orionis Biosciences BV | Interferón-gamma mutante diana y usos del mismo |
| JP7586579B2 (ja) | 2017-02-06 | 2024-11-19 | オリオンズ バイオサイエンス インコーポレイテッド | 標的化改変型インターフェロン及びその使用 |
| CN110546160A (zh) | 2017-02-06 | 2019-12-06 | 奥里尼斯生物科学公司 | 靶向嵌合蛋白及其用途 |
| US11246911B2 (en) | 2017-02-07 | 2022-02-15 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| CA3069994A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | Pd-1 and pd-l1 binding agents |
| EP3665201A4 (en) | 2017-08-09 | 2021-06-02 | Orionis Biosciences, Inc. | CD8 BINDERS |
| CN111511764B (zh) | 2017-08-09 | 2024-02-06 | 奥里尼斯生物科学有限公司 | Clec9a结合剂及其用途 |
| EP3973973A1 (en) | 2017-10-31 | 2022-03-30 | KaliVir Immunotherapeutics, Inc. | Platform oncolytic vector for systemic delivery |
| US20200354424A1 (en) | 2018-01-26 | 2020-11-12 | Orionis Biosciences, Inc. | Xcr1 binding agents and uses thereof |
| AU2019215440B2 (en) | 2018-02-05 | 2025-12-04 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
| US12084497B2 (en) | 2018-08-08 | 2024-09-10 | Orionis Biosciences, Inc. | SIRP1α targeted chimeric proteins and uses thereof |
| WO2020097350A1 (en) | 2018-11-08 | 2020-05-14 | Orionis Biosciences, Inc. | Modulation of dendritic cell lineages |
| KR20220012227A (ko) | 2019-03-28 | 2022-02-03 | 오리오니스 바이오사이언시즈 인코포레이티드 | Clec9a-기반 키메라 단백질 복합체 |
| CN113767115B (zh) | 2019-03-28 | 2025-05-02 | 奥里尼斯生物科学股份有限公司 | 治疗性干扰素α1蛋白 |
| CA3185087A1 (en) * | 2020-07-07 | 2022-01-13 | Nikolai Kley | Immunostimulatory adjuvants |
| AU2021385059A1 (en) | 2020-11-19 | 2023-06-08 | Kalivir Immunotherapeutics, Inc. | Oncolytic immunotherapy by tumor micro-environment remodeling |
| CR20230551A (es) | 2021-04-30 | 2024-05-07 | Kalivir Immunotherapeutics Inc | Virus oncolíticos para la expresión modificada del mhc |
| EP4622660A1 (en) * | 2022-11-21 | 2025-10-01 | Wisconsin Alumni Research Foundation | Synthetic il6-il1 beta fusion cytokine for promoting t cell cytotoxic function, t cell proliferation, and tumoricidal activity |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0489116B1 (en) * | 1989-08-22 | 1994-04-06 | Immunex Corporation | Fusion proteins comprising gm-csf and il-3 |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| WO2001010912A1 (en) * | 1999-08-09 | 2001-02-15 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| AU2002236517A1 (en) * | 2000-11-29 | 2002-06-11 | University Of Southern California | Targetet retoviral vectors for cancer immunotherapy |
| CN1168740C (zh) * | 2001-04-04 | 2004-09-29 | 上海美恩生物技术有限公司 | 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途 |
| EP1454138B1 (en) * | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| DE602004031341D1 (de) * | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| EP1598364A1 (en) * | 2004-05-21 | 2005-11-23 | AGIRx Limited | Chimerical soluble hyper IL-11 receptor and use thereof |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| EP2052081A1 (en) | 2006-08-02 | 2009-04-29 | McGill University | Fusion proteins and methods for modulation of immune response |
| WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| JP2010531666A (ja) | 2007-06-26 | 2010-09-30 | ユニバーシティ オブ マイアミ | 抗体−エンドスタチン融合タンパク質及びそのバリアント |
| MX2010003099A (es) | 2007-09-21 | 2010-05-17 | Univ California | Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales. |
| WO2010036918A2 (en) | 2008-09-26 | 2010-04-01 | University Of Massachusetts | Intracellular dna receptor |
| AU2009326075B2 (en) | 2008-12-08 | 2014-06-05 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| AU2010285071A1 (en) | 2009-08-17 | 2012-02-02 | Roche Glycart Ag | Targeted immunoconjugates |
| US20130115189A1 (en) | 2009-09-10 | 2013-05-09 | Cytos Biotechnology Ag | Use of Interleukin-1 Beta Mutein Conjugates in the Treatment of Diabetes |
| WO2011053991A2 (en) * | 2009-11-02 | 2011-05-05 | The Regents Of The University Of California | Vault complexes for cytokine delivery |
| EP2515916B1 (en) * | 2009-12-23 | 2016-03-09 | Gradalis, Inc. | Furin-knockdown and gm-csf-augmented (fang) cancer vaccine |
| CA2796706A1 (en) * | 2010-04-22 | 2011-10-27 | The Medical Research, Infrastructure, And Health Services Fund Of The Te L Aviv Medical Center | High affinity leptins and leptin antagonists |
| CN102372780A (zh) * | 2010-08-23 | 2012-03-14 | 上海市计划生育科学研究所 | 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用 |
| US9534056B2 (en) | 2011-06-06 | 2017-01-03 | Immungene Inc | Engineered TAA antibody-TNFSF member ligand fusion molecules |
| CN109022465B (zh) | 2011-10-28 | 2022-04-29 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| US9492562B2 (en) | 2012-01-20 | 2016-11-15 | Vib Vzw | Targeted human-interferon fusion proteins |
| HRP20200918T1 (hr) | 2012-03-03 | 2020-11-27 | Immungene, Inc. | Modificirane mutirane fuzijske molekule interferonskog antitijela |
| PE20170908A1 (es) * | 2014-10-29 | 2017-07-12 | Teva Pharmaceuticals Australia Pty Ltd | VARIANTES DE INTERFERON a2b |
-
2014
- 2014-07-03 WO PCT/EP2014/064227 patent/WO2015007536A2/en not_active Ceased
- 2014-07-03 SG SG11201600163VA patent/SG11201600163VA/en unknown
- 2014-07-03 ES ES17195867T patent/ES2757501T3/es active Active
- 2014-07-03 AU AU2014292371A patent/AU2014292371B2/en active Active
- 2014-07-03 KR KR1020167002676A patent/KR102322510B1/ko active Active
- 2014-07-03 CA CA2917937A patent/CA2917937C/en active Active
- 2014-07-03 ES ES14734831.2T patent/ES2657060T3/es active Active
- 2014-07-03 DK DK17195867T patent/DK3299466T3/da active
- 2014-07-03 CN CN201911159381.7A patent/CN110835376B/zh active Active
- 2014-07-03 EP EP17195867.1A patent/EP3299466B1/en active Active
- 2014-07-03 US US14/905,343 patent/US10640542B2/en active Active
- 2014-07-03 EP EP14734831.2A patent/EP3022305B1/en active Active
- 2014-07-03 SG SG10201808738WA patent/SG10201808738WA/en unknown
- 2014-07-03 JP JP2016526515A patent/JP6580037B2/ja active Active
- 2014-07-03 MX MX2016000611A patent/MX375441B/es active IP Right Grant
- 2014-07-03 BR BR112016001036-1A patent/BR112016001036B1/pt active IP Right Grant
- 2014-07-03 CN CN201480040538.3A patent/CN105705641B/zh active Active
-
2016
- 2016-01-03 IL IL24345116A patent/IL243451B/en active IP Right Grant
-
2018
- 2018-06-01 AU AU2018203868A patent/AU2018203868B2/en active Active
- 2018-08-14 US US16/103,302 patent/US11358997B2/en active Active
-
2019
- 2019-08-27 JP JP2019154901A patent/JP6853317B2/ja active Active
-
2022
- 2022-04-29 US US17/733,026 patent/US12410222B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525516A5 (cg-RX-API-DMAC7.html) | ||
| Weitzenfeld et al. | The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer | |
| JP2016529232A5 (cg-RX-API-DMAC7.html) | ||
| Koelink et al. | Targeting chemokine receptors in chronic inflammatory diseases: an extensive review | |
| Fedderke et al. | Does massive funding support of researchers work?: Evaluating the impact of the South African research chair funding initiative | |
| JP2016527221A5 (cg-RX-API-DMAC7.html) | ||
| EA201791137A1 (ru) | Новые замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств | |
| JP2016515522A5 (cg-RX-API-DMAC7.html) | ||
| WO2016073955A3 (en) | Cells lacking b2m surface expression and methods for allogeneic administration of such cells | |
| WO2015112886A3 (en) | Binding proteins and methods of use thereof | |
| WO2016090329A3 (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
| EP3749686A4 (en) | ADHESION RECEPTOR CONSTRUCTION AND THEIR USES IN NATURAL KILLER CELL IMMUNOTHERAPY | |
| MX373805B (es) | Agonistas de receptor fgf21 y usos del mismo. | |
| BR112016019837A2 (pt) | plasmídeos imunoestimuladores | |
| EP3243830A4 (en) | Protein associated with disease resistance and encoding gene thereof, and use thereof in regulation of plant disease resistance | |
| WO2016081885A3 (en) | Panel-based genetic diagnostic testing for inherited eye diseases | |
| CN110198953A (zh) | 针对ny-eso的高亲和力tcr | |
| Whistler | Patwin folk-taxonomic structures | |
| EP3875470A4 (en) | CHIMERIC ANTIGEN WITH ENHANCED MULTI-IMMUNE FUNCTION BY SPECIFIC BINDING TO A TARGET CELL, AND USE THEREOF | |
| Chellaraj et al. | Internal and international remittances in India: Implications for household expenditure and poverty | |
| Kellogg | Photographs-Travels-Africa, 1925-1926 | |
| Starzyńska et al. | III ogólnopolska konferencja naukowa „Zarządzanie współczesnymi przedsiębiorstwami. Współczesne problemy gospodarcze w oczach młodego pokolenia”: Third National Scientific Conference „Managing today's enterprises. Contemporary economic problems in the eyes of the young generation” | |
| 柴山史朗 | IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity. | |
| Mitra | Criminology-Crime and Correctional Administration | |
| Rolland | Mahatma Gandhi by Romain Rolland |